GLP1R and type 2 diabetes mellitus: Trials of combining insulin with other drugs to control T2D (GLP-1 RA, DDP-4i, and SGLT2i) suggest that such treatment could lead to the use of reduced doses of insulin, less weight gain, and fewer episodes of hypoglycemia compared with the insulin monotherapy.